New drug targets Hard-to-Treat cancers with PIK3CA mutation
Disease control
Not yet recruiting
This early-phase study tests an experimental drug called CGT6297 in 90 adults whose advanced solid tumors (including certain breast and endometrial cancers) have a specific genetic change called PIK3CA. The main goals are to check the drug's safety and find the best dose, while a…
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC